CN102631874A - 纳米分散体的相关改进 - Google Patents
纳米分散体的相关改进 Download PDFInfo
- Publication number
- CN102631874A CN102631874A CN2012101088434A CN201210108843A CN102631874A CN 102631874 A CN102631874 A CN 102631874A CN 2012101088434 A CN2012101088434 A CN 2012101088434A CN 201210108843 A CN201210108843 A CN 201210108843A CN 102631874 A CN102631874 A CN 102631874A
- Authority
- CN
- China
- Prior art keywords
- water
- solvent
- useful load
- carrier material
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000463 material Substances 0.000 claims abstract description 120
- 239000002904 solvent Substances 0.000 claims abstract description 77
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 239000012876 carrier material Substances 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 57
- 239000007787 solid Substances 0.000 claims abstract description 31
- 239000002105 nanoparticle Substances 0.000 claims abstract description 29
- 239000006185 dispersion Substances 0.000 claims abstract description 27
- 238000001035 drying Methods 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 99
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 80
- 239000003125 aqueous solvent Substances 0.000 claims description 66
- 239000004094 surface-active agent Substances 0.000 claims description 41
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 35
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 30
- 239000002202 Polyethylene glycol Substances 0.000 claims description 20
- 229920001223 polyethylene glycol Polymers 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 19
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 17
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 12
- 239000002198 insoluble material Substances 0.000 claims description 12
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 8
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- 239000000969 carrier Substances 0.000 claims description 7
- 239000002736 nonionic surfactant Substances 0.000 claims description 7
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 6
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000002195 soluble material Substances 0.000 abstract description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 70
- 239000000243 solution Substances 0.000 description 48
- 239000000843 powder Substances 0.000 description 35
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 31
- 238000001694 spray drying Methods 0.000 description 30
- 239000000047 product Substances 0.000 description 27
- -1 before drying steps Substances 0.000 description 20
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 18
- 239000003921 oil Substances 0.000 description 17
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 17
- 239000012153 distilled water Substances 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 14
- 239000007921 spray Substances 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 239000002245 particle Substances 0.000 description 11
- 239000004064 cosurfactant Substances 0.000 description 10
- 229920001451 polypropylene glycol Polymers 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 239000005747 Chlorothalonil Substances 0.000 description 6
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 description 6
- 239000006184 cosolvent Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000011877 solvent mixture Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- VKWNTWQXVLKCSG-ZDXBJJIESA-N Sudan Red 7B Chemical compound CCNC1=CC=C2C=CC=CC2=C1\N=N\C(C=C1)=CC=C1\N=N\C1=CC=CC=C1 VKWNTWQXVLKCSG-ZDXBJJIESA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000007844 bleaching agent Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 229920001610 polycaprolactone Polymers 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000855 fungicidal effect Effects 0.000 description 4
- 239000000417 fungicide Substances 0.000 description 4
- FTODBIPDTXRIGS-ZDUSSCGKSA-N homoeriodictyol Chemical compound C1=C(O)C(OC)=CC([C@H]2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-ZDUSSCGKSA-N 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 4
- 239000006104 solid solution Substances 0.000 description 4
- 229920003169 water-soluble polymer Polymers 0.000 description 4
- OWEGWHBOCFMBLP-UHFFFAOYSA-N 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one Chemical compound C1=CN=CN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 OWEGWHBOCFMBLP-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960003344 climbazole Drugs 0.000 description 3
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 238000001033 granulometry Methods 0.000 description 3
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 3
- 229910010272 inorganic material Inorganic materials 0.000 description 3
- 239000011147 inorganic material Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 229940073450 sudan red Drugs 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- ZXQYGBMAQZUVMI-RDDWSQKMSA-N (1S)-cis-(alphaR)-cyhalothrin Chemical compound CC1(C)[C@H](\C=C(/Cl)C(F)(F)F)[C@@H]1C(=O)O[C@@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-RDDWSQKMSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 2
- VGMJYYDKPUPTID-UHFFFAOYSA-N 4-ethylbenzene-1,3-diol Chemical compound CCC1=CC=C(O)C=C1O VGMJYYDKPUPTID-UHFFFAOYSA-N 0.000 description 2
- YGUMVDWOQQJBGA-VAWYXSNFSA-N 5-[(4-anilino-6-morpholin-4-yl-1,3,5-triazin-2-yl)amino]-2-[(e)-2-[4-[(4-anilino-6-morpholin-4-yl-1,3,5-triazin-2-yl)amino]-2-sulfophenyl]ethenyl]benzenesulfonic acid Chemical compound C=1C=C(\C=C\C=2C(=CC(NC=3N=C(N=C(NC=4C=CC=CC=4)N=3)N3CCOCC3)=CC=2)S(O)(=O)=O)C(S(=O)(=O)O)=CC=1NC(N=C(N=1)N2CCOCC2)=NC=1NC1=CC=CC=C1 YGUMVDWOQQJBGA-VAWYXSNFSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- 239000003905 agrochemical Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000005910 lambda-Cyhalothrin Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229920005573 silicon-containing polymer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
- 150000005003 1-naphthylamines Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- XRPDDDRNQJNHLQ-UHFFFAOYSA-N 2-ethyl-1h-pyrrole Chemical class CCC1=CC=CN1 XRPDDDRNQJNHLQ-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical class C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000005784 Fluoxastrobin Substances 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 239000004347 Glyceryl monoacetate Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000005822 Propiconazole Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 229920002000 Xyloglucan Polymers 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229920005605 branched copolymer Polymers 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000002979 fabric softener Substances 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- UFEODZBUAFNAEU-NLRVBDNBSA-N fluoxastrobin Chemical compound C=1C=CC=C(OC=2C(=C(OC=3C(=CC=CC=3)Cl)N=CN=2)F)C=1C(=N/OC)\C1=NOCCO1 UFEODZBUAFNAEU-NLRVBDNBSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000019442 glyceryl monoacetate Nutrition 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
- 101150107144 hemC gene Proteins 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- STJLVHWMYQXCPB-UHFFFAOYSA-N propiconazole Chemical compound O1C(CCC)COC1(C=1C(=CC(Cl)=CC=1)Cl)CN1N=CN=C1 STJLVHWMYQXCPB-UHFFFAOYSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000000344 soap Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0613925.7 | 2006-07-13 | ||
| GBGB0613925.7A GB0613925D0 (en) | 2006-07-13 | 2006-07-13 | Improvements relating to nanodispersions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800263679A Division CN101489535A (zh) | 2006-07-13 | 2007-06-29 | 纳米分散体的相关改进 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102631874A true CN102631874A (zh) | 2012-08-15 |
Family
ID=36955583
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800263679A Pending CN101489535A (zh) | 2006-07-13 | 2007-06-29 | 纳米分散体的相关改进 |
| CN201010193750A Pending CN101849911A (zh) | 2006-07-13 | 2007-06-29 | 生物杀伤剂组合物的相关改进 |
| CNA2007800262657A Pending CN101489532A (zh) | 2006-07-13 | 2007-06-29 | 与药物组合物相关的改进 |
| CNA2007800262750A Pending CN101489533A (zh) | 2006-07-13 | 2007-06-29 | 生物希伤剂组合物的相关改进 |
| CN2012101088434A Pending CN102631874A (zh) | 2006-07-13 | 2007-06-29 | 纳米分散体的相关改进 |
| CNA2007800263575A Pending CN101489534A (zh) | 2006-07-13 | 2007-06-29 | 抗寄生虫组合物的相关改进 |
| CNA2007800262267A Pending CN101489531A (zh) | 2006-07-13 | 2007-06-29 | 与药物组合物相关的改进 |
| CN2012101088167A Pending CN102671585A (zh) | 2006-07-13 | 2007-06-29 | 纳米分散体的相关改进 |
| CNA2007800338285A Pending CN101516340A (zh) | 2006-07-13 | 2007-07-13 | 制备药学制剂 |
| CNA2007800338444A Pending CN101516341A (zh) | 2006-07-13 | 2007-07-13 | 制备药学组合物 |
| CNA2007800338942A Pending CN101516342A (zh) | 2006-07-13 | 2007-07-13 | 制备药学组合物的方法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800263679A Pending CN101489535A (zh) | 2006-07-13 | 2007-06-29 | 纳米分散体的相关改进 |
| CN201010193750A Pending CN101849911A (zh) | 2006-07-13 | 2007-06-29 | 生物杀伤剂组合物的相关改进 |
| CNA2007800262657A Pending CN101489532A (zh) | 2006-07-13 | 2007-06-29 | 与药物组合物相关的改进 |
| CNA2007800262750A Pending CN101489533A (zh) | 2006-07-13 | 2007-06-29 | 生物希伤剂组合物的相关改进 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800263575A Pending CN101489534A (zh) | 2006-07-13 | 2007-06-29 | 抗寄生虫组合物的相关改进 |
| CNA2007800262267A Pending CN101489531A (zh) | 2006-07-13 | 2007-06-29 | 与药物组合物相关的改进 |
| CN2012101088167A Pending CN102671585A (zh) | 2006-07-13 | 2007-06-29 | 纳米分散体的相关改进 |
| CNA2007800338285A Pending CN101516340A (zh) | 2006-07-13 | 2007-07-13 | 制备药学制剂 |
| CNA2007800338444A Pending CN101516341A (zh) | 2006-07-13 | 2007-07-13 | 制备药学组合物 |
| CNA2007800338942A Pending CN101516342A (zh) | 2006-07-13 | 2007-07-13 | 制备药学组合物的方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (10) | US9060937B2 (enExample) |
| EP (8) | EP2040681B1 (enExample) |
| JP (9) | JP2009542760A (enExample) |
| CN (11) | CN101489535A (enExample) |
| AP (1) | AP2008004713A0 (enExample) |
| AR (4) | AR061992A1 (enExample) |
| AU (9) | AU2007271829B2 (enExample) |
| BR (8) | BRPI0714179A2 (enExample) |
| CA (8) | CA2659666A1 (enExample) |
| CL (4) | CL2007002031A1 (enExample) |
| ES (2) | ES2741124T3 (enExample) |
| GB (1) | GB0613925D0 (enExample) |
| IL (2) | IL195911A0 (enExample) |
| MX (2) | MX2009000309A (enExample) |
| TW (1) | TW200812694A (enExample) |
| WO (8) | WO2008006716A2 (enExample) |
| ZA (7) | ZA200900030B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110074993A (zh) * | 2019-06-05 | 2019-08-02 | 山东大学 | 一种制备紫外吸收剂纳米颗粒的方法 |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0501833D0 (en) * | 2005-01-28 | 2005-03-09 | Unilever Plc | Carrier liquids and methods of production thereof |
| WO2007133758A1 (en) * | 2006-05-15 | 2007-11-22 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
| GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
| WO2008022651A1 (en) | 2006-08-21 | 2008-02-28 | Antoine Turzi | Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells |
| AR063704A1 (es) | 2006-09-14 | 2009-02-11 | Makhteshim Chem Works Ltd | Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones |
| EP2124556B1 (en) | 2006-10-09 | 2014-09-03 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| EP2170313A2 (en) * | 2007-06-18 | 2010-04-07 | Combino Pharm, S.L. | Aqueous formulations of acetaminophen for injection |
| AR067047A1 (es) * | 2007-06-18 | 2009-09-30 | Combino Pharm Sl | Formulaciones acuosas de acetaminofen para inyeccion. |
| ES2731881T3 (es) | 2007-09-25 | 2019-11-19 | Formulex Pharma Innovations Ltd | Composiciones que comprenden compuestos activos lipófilos y método para su preparación |
| CA2905541C (en) | 2008-01-09 | 2020-02-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| TR200800634A2 (tr) * | 2008-01-30 | 2009-02-23 | Takka Sevgi̇ | Uzatılmış salım sağlayan fluvastatin tablet. |
| US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| AU2009223061B2 (en) * | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| US20110117157A1 (en) * | 2008-07-11 | 2011-05-19 | Nippon Soda Co., Ltd. | Method of manufacture of sustained-release formulation composition |
| GB0814953D0 (en) * | 2008-08-18 | 2008-09-24 | Unilever Plc | Improvements relating to nanodisperse compositions |
| CA2737452C (en) | 2008-09-25 | 2018-05-22 | Vive Nano Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
| FR2938433B1 (fr) * | 2008-11-19 | 2011-09-09 | Francois Fauran | Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation |
| WO2010082840A1 (en) * | 2008-12-12 | 2010-07-22 | Tim Tech Chemicals Limited | Compositions for the treatment of timber and other wood substrates |
| EP2243477A1 (de) * | 2009-04-22 | 2010-10-27 | Fresenius Kabi Deutschland GmbH | Paracetamol zur parenteralen Verabreichung |
| WO2010137888A2 (ko) * | 2009-05-27 | 2010-12-02 | 주식회사 삼양사 | 생체이용률이 향상된 난용성 약물 함유 미립구 및 그 제조 방법 |
| HUP0900376A2 (en) * | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate candesartan cilexetil composition |
| HUP0900384A2 (en) * | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate olmesartan medoxomil compositions |
| KR101817986B1 (ko) * | 2009-06-25 | 2018-01-16 | 진양제약주식회사 | 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법 |
| EP3311667A1 (en) | 2009-07-08 | 2018-04-25 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| KR20120059582A (ko) * | 2009-08-31 | 2012-06-08 | 데포메드 인코퍼레이티드 | 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물 |
| JP5498769B2 (ja) * | 2009-12-04 | 2014-05-21 | 花王株式会社 | 脂溶性薬物内包ナノ粒子の製造方法 |
| US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| SI2536396T1 (sl) | 2010-02-16 | 2017-01-31 | KRKA, tovarna zdravil, d.d.,Novo mesto | Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan |
| JP5602936B2 (ja) | 2010-03-29 | 2014-10-08 | フイルメニツヒ ソシエテ アノニム | 噴霧乾燥した結晶性活性成分 |
| GB201006038D0 (en) * | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
| UA111167C2 (uk) * | 2010-08-05 | 2016-04-11 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Пестицидні композиції мезорозмірних частинок з підсиленою дією |
| CN103249406A (zh) | 2010-10-05 | 2013-08-14 | 阿尔塔纳米产品有限公司 | 一种用于制备改进的组合物的方法 |
| US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
| US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
| WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
| US8637038B2 (en) | 2011-04-12 | 2014-01-28 | Rigel Pharmaceuticals, Inc. | Methods for inhibiting allograft rejection |
| US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
| US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
| US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
| US9308190B2 (en) | 2011-06-06 | 2016-04-12 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
| JP2013001771A (ja) * | 2011-06-14 | 2013-01-07 | Neos Co Ltd | 液状カビ防除洗浄剤組成物 |
| RU2469536C1 (ru) * | 2011-06-16 | 2012-12-20 | Государственное бюджетное учреждение Республики Башкортостан "Научно-исследовательский технологический институт гербицидов и регуляторов роста растений с опытно-экспериментальным производством Академии наук Республики Башкортостан" | Фунгицидное средство и способ его получения |
| EA032840B8 (ru) | 2011-06-22 | 2020-06-18 | Вайоми Терапеутикс Лимитед | Пролекарства на основе конъюгатов противогрибковых агентов и их применение |
| CN104039140B (zh) | 2011-08-23 | 2017-07-21 | 维弗作物保护公司 | 拟除虫菊酯配制品 |
| GB201115079D0 (en) | 2011-08-31 | 2011-10-19 | Iota Nanosolutions Ltd | Method of preparing carrier liquids |
| GB201115633D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of efavirenz |
| GB201115635D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of lopinavir and ritonavir |
| GB201115634D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of lopinavir |
| US8609684B2 (en) | 2011-12-12 | 2013-12-17 | PruGen IP Holdings, Inc. | Solubilization and bioavailability of acetaminophen |
| EP2793574A4 (en) | 2011-12-22 | 2015-09-02 | Vive Crop Prot Inc | STROBILURINFORMULIERUNGEN |
| JP6247685B2 (ja) * | 2012-05-16 | 2017-12-13 | メワ・シン | 実質的に水不溶性の薬物の送達のための医薬組成物 |
| MX362838B (es) | 2012-07-12 | 2019-02-19 | SpecGx LLC | Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente. |
| US20140073678A1 (en) * | 2012-09-12 | 2014-03-13 | Monosol Rx, Llc | Anti-pain and anti-nausea and/or vomiting combinatorial compositions |
| HK1217409A1 (zh) | 2013-06-04 | 2017-01-13 | 维奥姆生物科学有限公司 | 涂布的颗粒和包括其的组合物 |
| AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9925241B2 (en) | 2013-10-21 | 2018-03-27 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (FGF) 1 and methods of use |
| EP4173619A3 (en) * | 2013-11-13 | 2023-07-19 | National Defense Education and Research Foundation | New acetaminophen compound composition without side effect to liver |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| EP3119415A4 (en) | 2014-03-07 | 2017-11-29 | The Arizona Board of Regents on behalf of the University of Arizona | Non-narcotic crmp2 peptides targeting sodium channels for chronic pain |
| EP2952208A1 (en) * | 2014-06-04 | 2015-12-09 | Universidade de Santiago de Compostela | Hydroalcoholic system for nail treatment |
| AU2015275098B2 (en) | 2014-06-11 | 2018-12-06 | SpecGx LLC | Spray dried compositions having different dissolution profiles and processes for their preparation |
| CN104042626A (zh) * | 2014-07-01 | 2014-09-17 | 李绍明 | 杀菌抑菌剂 |
| WO2016010771A1 (en) | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| CA2964628A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| JP2018502742A (ja) * | 2014-12-23 | 2018-02-01 | ダウ グローバル テクノロジーズ エルエルシー | 処理済み多孔質材料 |
| JP6730315B2 (ja) * | 2015-01-20 | 2020-07-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 担体ポリマーとしてのポリビニルアルコールを用いた化合物の固体分散体 |
| CN104798772B (zh) * | 2015-03-13 | 2017-05-24 | 中国农业科学院农业环境与可持续发展研究所 | 一种农药纳米固体分散体及其制备方法 |
| US10034857B2 (en) | 2015-07-02 | 2018-07-31 | Civitas Therapeutics, Inc. | Triptan powders for pulmonary delivery |
| EP3324959B1 (en) | 2015-07-17 | 2023-07-12 | The Board Of Regents Of The University Of Oklahoma | Licofelone derivatives and methods of use |
| CN105145553A (zh) * | 2015-10-12 | 2015-12-16 | 广西田园生化股份有限公司 | 一种难溶农药的固体分散体组合物 |
| ES2812155T3 (es) * | 2016-02-02 | 2021-03-16 | Evonik Operations Gmbh | Formulaciones pulverulentas de sustancias tensioactivas sobre soportes sólidos hidrosolubles, procedimientos para su producción, así como su empleo |
| WO2017152130A1 (en) | 2016-03-04 | 2017-09-08 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| CA3027817C (en) * | 2016-06-16 | 2023-12-19 | The University Of Liverpool | Chemical composition for the treatment and prophylaxis of systemic infections |
| RU2619249C1 (ru) * | 2016-11-07 | 2017-05-12 | Федеральное государственное бюджетное учреждение науки Институт химии твердого тела и механохимии Сибирского отделения Российской академии наук (ИХТТМ СО РАН) | Композиция для протравливания семян и способ её получения |
| WO2018160772A1 (en) | 2017-02-28 | 2018-09-07 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis |
| EP3601301A1 (en) | 2017-03-31 | 2020-02-05 | The University of Liverpool | Prodrug compositions |
| US20210015752A1 (en) * | 2017-06-15 | 2021-01-21 | Savior Lifetec Corporation | Methods for producing particles of an active ingredient |
| US11517013B2 (en) | 2017-08-25 | 2022-12-06 | Vive Crop Protection Inc. | Multi-component, soil-applied, pesticidal compositions |
| US20210361639A1 (en) | 2018-03-02 | 2021-11-25 | The University Of Liverpool | Solid compositions of actives, processes for preparing same and uses of such solid compositions |
| JP6858729B2 (ja) * | 2018-05-25 | 2021-04-14 | ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成 |
| US20210346462A1 (en) | 2018-10-04 | 2021-11-11 | Rutgers, The State University Of New Jersey | Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides |
| WO2020135600A1 (zh) * | 2018-12-28 | 2020-07-02 | 南京善思生物科技有限公司 | 纳米农药制剂及其制备方法 |
| CN109846821B (zh) * | 2019-01-03 | 2021-07-06 | 昆药集团股份有限公司 | 一种蒿甲醚纳米制剂及其制备方法 |
| US20220054494A1 (en) | 2019-03-13 | 2022-02-24 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for treating bladder and urethra dysfunction and disease |
| MX2021015576A (es) * | 2019-06-28 | 2022-03-02 | Solstar Pharma | Formulacion gastroretentiva de liberacion extendida contra helicobacter pylori. |
| WO2021062012A1 (en) | 2019-09-25 | 2021-04-01 | Emory University | Use of klk10 and engineered derivatizations thereof |
| CN114615889A (zh) * | 2019-10-28 | 2022-06-10 | 组合化学工业株式会社 | 农药组合物及其制造方法 |
| CA3165922A1 (en) | 2020-01-17 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene therapy for treatment of crx-autosomal dominant retinopathies |
| US20230181672A1 (en) | 2020-05-07 | 2023-06-15 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms |
| IT202000022789A1 (it) | 2020-09-28 | 2020-12-28 | Vitop Moulding Srl | Rubinetto erogatore provvisto di sistema di collocamento, bloccaggio e orientamento su scatole di tipo Bag-In-Box |
| GB202115049D0 (en) | 2021-10-20 | 2021-12-01 | Univ Liverpool | Chemical Compositions |
| WO2023196898A1 (en) | 2022-04-07 | 2023-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta globin mimetic peptides and their use |
| CN114732009B (zh) * | 2022-06-13 | 2022-08-23 | 山东百农思达生物科技有限公司 | 一种含有吡唑醚菌酯和烯酰吗啉的水分散粒剂的制备方法 |
| AU2024240009A1 (en) | 2023-03-17 | 2025-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for treatment of age-related macular degeneration |
| GB202304657D0 (en) | 2023-03-29 | 2023-05-10 | Univ Liverpool | Atovaquine compositions |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB501835A (en) | 1936-05-29 | 1939-03-02 | Siemens Ag | Process and apparatus for reducing the power required for the mechanical treatment of movable masses |
| GB1305024A (enExample) * | 1969-07-10 | 1973-01-31 | ||
| GB1554662A (en) * | 1976-05-05 | 1979-10-24 | Inverni Della Beffa Spa | Polyhydroxyphenylchromanones |
| US4230687A (en) * | 1978-05-30 | 1980-10-28 | Griffith Laboratories U.S.A., Inc. | Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices |
| DE3439482A1 (de) * | 1984-10-27 | 1986-05-07 | Röhm GmbH, 6100 Darmstadt | Verfahren zur beschichtung von substraten mit kratzfesten, nichtreflektierenden ueberzuegen |
| US4830858A (en) * | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
| US5160530A (en) * | 1989-01-24 | 1992-11-03 | Griffin Corporation | Microencapsulated polymorphic agriculturally active material |
| GB8918807D0 (en) * | 1989-08-17 | 1989-09-27 | Shell Int Research | A solid pesticidal formulation,a process for its preparation and the use thereof |
| JP3067810B2 (ja) * | 1990-12-21 | 2000-07-24 | 中外製薬株式会社 | 経口投与用ｏ／ｗ型エマルジョンの乾燥粉末製造法 |
| GB9304294D0 (en) * | 1993-03-03 | 1993-04-21 | Zeneca Ltd | Herbicidal compositions |
| DE4329446A1 (de) * | 1993-09-01 | 1995-03-02 | Basf Ag | Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen |
| US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
| TW318777B (enExample) * | 1995-06-29 | 1997-11-01 | Novartis Ag | |
| EP0862420A4 (en) | 1995-10-13 | 1999-11-03 | Penn State Res Found | SYNTHESIS OF DRUG SPRAY DRUG NANOPARTICLES |
| GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
| US5858409A (en) | 1996-04-17 | 1999-01-12 | Fmc Corporation | Hydrolyzed cellulose granulations for pharmaceuticals |
| US5976574A (en) | 1996-12-31 | 1999-11-02 | Inhale Therapeutic Systems | Processes for spray drying hydrophobic drugs in organic solvent suspensions |
| JP4183279B2 (ja) * | 1997-04-15 | 2008-11-19 | アール ピー シェーラー テクノロジーズ インコーポレーテッド | 医薬用加水分解セルロース顆粒 |
| EP1080720A4 (en) * | 1998-03-05 | 2002-06-05 | Nippon Shinyaku Co Ltd | FAT EMULSIONS FOR INHALATIVE ADMINISTRATION |
| JPH11322587A (ja) | 1998-05-18 | 1999-11-24 | Sumitomo Chem Co Ltd | 常温で固体の生理活性物質のマイクロカプセル化方法およびこの方法により得られるマイクロカプセル組成物 |
| WO2000040220A1 (en) * | 1999-01-06 | 2000-07-13 | Korea Research Institute Of Chemical Technology | Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same |
| EP1027886B1 (en) * | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
| GB9904012D0 (en) | 1999-02-22 | 1999-04-14 | Zeneca Ltd | Agrochemical formulation |
| US6610317B2 (en) | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
| IL146659A0 (en) * | 1999-05-27 | 2002-07-25 | Acusphere Inc | Porous drug matrices and method of manufacture thereof |
| US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
| GB9920148D0 (en) * | 1999-08-25 | 1999-10-27 | Smithkline Beecham Plc | Novel composition |
| CA2392810A1 (en) | 1999-12-01 | 2001-06-07 | Natco Pharma Limited | A rapid acting freeze dired oral pharmaceutical composition for treating migraine |
| KR100694667B1 (ko) * | 1999-12-08 | 2007-03-14 | 동아제약주식회사 | 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제 |
| US6207674B1 (en) * | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
| US20020044969A1 (en) | 2000-05-22 | 2002-04-18 | Jerome Harden | Method for increasing the compressibility of poorly binding powder materials |
| US6932963B2 (en) * | 2000-06-23 | 2005-08-23 | Nicholas V. Perricone | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
| IT1318618B1 (it) | 2000-07-10 | 2003-08-27 | A C R Applied Coating Res S A | Microsfere bioadesive a rilascio rapido per la somministrazionesublinguale di principi attivi. |
| CA2416600A1 (en) * | 2000-07-24 | 2003-01-20 | Ono Pharmaceutical Co., Ltd. | Freeze-dried preparation of n-¬o-(p-pivaloyloxybenzenesulfonylamino)benzoyl|glycine monosodium salt tetrahydrate and a process for the maufacture thereof |
| DE10036871A1 (de) * | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe |
| EP1322289B1 (en) * | 2000-09-20 | 2007-07-25 | Jagotec AG | Spray drying process of compositions containing fenofibrate |
| US6756062B2 (en) * | 2000-11-03 | 2004-06-29 | Board Of Regents University Of Texas System | Preparation of drug particles using evaporation precipitation into aqueous solutions |
| US8067032B2 (en) * | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
| US6862890B2 (en) * | 2001-01-30 | 2005-03-08 | Board Of Regents, University Of Texas System | Process for production of nanoparticles and microparticles by spray freezing into liquid |
| US6355675B1 (en) | 2001-05-15 | 2002-03-12 | Isp Investments Inc. | Emulsifiable concentrate of a water-insoluble fungicide |
| MXPA03011017A (es) * | 2001-06-01 | 2005-04-29 | Pozen Inc | Composiciones farmaceuticas para la entrega coordinada de nsaids. |
| ATE480226T1 (de) * | 2001-06-22 | 2010-09-15 | Bend Res Inc | Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere |
| KR100425226B1 (ko) * | 2001-07-03 | 2004-03-30 | 주식회사 팜트리 | 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법 |
| WO2003017659A1 (fr) * | 2001-08-21 | 2003-02-27 | Sony Corporation | Systeme de traitement de donnees, dispositif et procede de traitement de donnees |
| US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| WO2003026611A2 (en) | 2001-09-26 | 2003-04-03 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| DE10151392A1 (de) * | 2001-10-18 | 2003-05-08 | Bayer Cropscience Ag | Pulverförmige Feststoff-Formulierungen |
| US20040242427A1 (en) * | 2001-11-07 | 2004-12-02 | Sebastian Koltzenburg | Cinidon-ethyl containing solid crop protection formulations and corresponding dispersions |
| DE60211029T2 (de) * | 2001-11-07 | 2006-08-31 | Basf Ag | Nanopartikel enthaltend ein pflanzenschutzmittel |
| WO2003063822A2 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| JP2005522424A (ja) * | 2002-02-01 | 2005-07-28 | ファイザー・プロダクツ・インク | コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態 |
| US6780324B2 (en) * | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| US20040028505A1 (en) * | 2002-06-07 | 2004-02-12 | Bilbrey Robert A. | Document tape binding system with automatic tape feed, tape indicia sensing, spine printing method and post-bind automation mechanisms |
| CA2488499C (en) | 2002-06-10 | 2013-03-19 | Elan Pharma International Ltd. | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions |
| US20030017208A1 (en) * | 2002-07-19 | 2003-01-23 | Francis Ignatious | Electrospun pharmaceutical compositions |
| DE10244681A1 (de) * | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
| JP2006501936A (ja) * | 2002-10-04 | 2006-01-19 | エラン ファーマ インターナショナル，リミティド | 固体ナノ粒子活性薬剤のガンマ線照射 |
| CN1176649C (zh) | 2002-10-16 | 2004-11-24 | 上海医药工业研究院 | 舒马普坦干粉吸入剂及其制备方法 |
| US20040220081A1 (en) * | 2002-10-30 | 2004-11-04 | Spherics, Inc. | Nanoparticulate bioactive agents |
| EP1575566B1 (en) * | 2002-12-26 | 2012-02-22 | Pozen, Inc. | Multilayer dosage forms containing naproxen and triptans |
| JP2006520746A (ja) * | 2002-12-27 | 2006-09-14 | カイロン コーポレイション | リン脂質を含む免疫原性組成物 |
| AU2004206109A1 (en) * | 2003-01-21 | 2004-08-05 | Ranbaxy Laboratories Limited | Co-precipitated amorphous losartan and dosage forms comprising the same |
| US20040197301A1 (en) * | 2003-02-18 | 2004-10-07 | Zhong Zhao | Hybrid polymers and methods of making the same |
| CA2514875A1 (en) * | 2003-02-19 | 2004-09-02 | Biovail Laboratories International Srl | Rapid absorption selective 5-ht agonist formulations |
| WO2004075921A1 (en) * | 2003-02-26 | 2004-09-10 | Vrije Universiteit Brussel | Inclusion complex of artemisinin or derivates thereof with cyclodextrins |
| MXPA05010821A (es) | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico. |
| US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| CA2465565A1 (en) | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| CA2532450C (en) * | 2003-07-16 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Chlorthalidone combinations |
| US7687167B2 (en) * | 2003-07-18 | 2010-03-30 | Panasonic Corporation | Power supply unit |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| DE10338403A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
| DE10351004A1 (de) * | 2003-10-30 | 2005-05-25 | Basf Ag | Nanopartikuläre Wirkstoffformulierungen |
| DE10351087A1 (de) * | 2003-10-31 | 2005-05-25 | Bayer Technology Services Gmbh | Feste Wirkstoff-Formulierung |
| KR100603974B1 (ko) * | 2003-12-05 | 2006-07-25 | 김갑식 | 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법 |
| JP2007517015A (ja) * | 2003-12-31 | 2007-06-28 | ファイザー・プロダクツ・インク | 低溶解性薬物、ポロキサマーおよび安定化ポリマーの安定化された医薬用固体組成物 |
| KR100629771B1 (ko) * | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
| IL160095A0 (en) | 2004-01-28 | 2004-06-20 | Yissum Res Dev Co | Formulations for poorly soluble drugs |
| JP2005298347A (ja) * | 2004-04-06 | 2005-10-27 | Yoshiaki Kawashima | 吸入製剤及びその製造方法 |
| KR100598326B1 (ko) * | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법 |
| RU2006141846A (ru) * | 2004-04-28 | 2008-06-10 | Юнилевер Н.В. (Nl) | Пищевое масло, содержащее статины |
| WO2005117834A1 (en) * | 2004-05-27 | 2005-12-15 | Janssen Pharmaceutica N.V. | Solid dispersions of a basic drug compound and a polymer containing acidic groups |
| DK1641438T3 (da) | 2004-06-01 | 2010-06-07 | Teva Gyogyszergyar Zartkoeruen | Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel |
| DE102004031298A1 (de) | 2004-06-28 | 2006-01-12 | Basf Ag | Wässrige Dispersionen schwer wasserlöslicher oder wasserunlöslicher Wirkstoffe und daraus hergestellte Trockenpulver enthaltend mindestens ein Polyethergruppen enthaltendes Polymer als Schutzkolloid |
| WO2006038552A1 (ja) * | 2004-10-01 | 2006-04-13 | Eisai R & D Management Co., Ltd. | 微粒子含有組成物およびその製造方法 |
| US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
| CN101132770A (zh) * | 2005-01-06 | 2008-02-27 | 伊兰制药国际有限公司 | 纳米微粒坎地沙坦制剂 |
| GB0501835D0 (en) * | 2005-01-28 | 2005-03-09 | Unilever Plc | Improvements relating to spray dried compositions |
| GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
| WO2008076780A2 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments Inc. | Amorphous valsartan and the production thereof |
-
2006
- 2006-07-13 GB GBGB0613925.7A patent/GB0613925D0/en not_active Ceased
-
2007
- 2007-06-29 EP EP07786933.7A patent/EP2040681B1/en active Active
- 2007-06-29 CN CNA2007800263679A patent/CN101489535A/zh active Pending
- 2007-06-29 WO PCT/EP2007/056564 patent/WO2008006716A2/en not_active Ceased
- 2007-06-29 US US12/309,292 patent/US9060937B2/en active Active
- 2007-06-29 EP EP07786931A patent/EP2040679A2/en not_active Ceased
- 2007-06-29 CA CA002659666A patent/CA2659666A1/en not_active Abandoned
- 2007-06-29 JP JP2009518831A patent/JP2009542760A/ja active Pending
- 2007-06-29 AU AU2007271829A patent/AU2007271829B2/en not_active Ceased
- 2007-06-29 US US12/309,293 patent/US20090239749A1/en not_active Abandoned
- 2007-06-29 CN CN201010193750A patent/CN101849911A/zh active Pending
- 2007-06-29 CA CA002656223A patent/CA2656223A1/en not_active Abandoned
- 2007-06-29 BR BRPI0714179-3A patent/BRPI0714179A2/pt not_active IP Right Cessation
- 2007-06-29 CN CNA2007800262657A patent/CN101489532A/zh active Pending
- 2007-06-29 BR BRPI0714176-9A patent/BRPI0714176A2/pt not_active IP Right Cessation
- 2007-06-29 AU AU2007271827A patent/AU2007271827B2/en not_active Ceased
- 2007-06-29 MX MX2009000309A patent/MX2009000309A/es not_active Application Discontinuation
- 2007-06-29 US US12/309,295 patent/US20100015233A1/en not_active Abandoned
- 2007-06-29 JP JP2009518832A patent/JP2009542761A/ja active Pending
- 2007-06-29 EP EP07765733.6A patent/EP2040677B1/en active Active
- 2007-06-29 ES ES07765733T patent/ES2741124T3/es active Active
- 2007-06-29 WO PCT/EP2007/056562 patent/WO2008006714A2/en not_active Ceased
- 2007-06-29 JP JP2009518835A patent/JP2009542764A/ja active Pending
- 2007-06-29 EP EP20100175541 patent/EP2269581A1/en not_active Withdrawn
- 2007-06-29 ZA ZA200900030A patent/ZA200900030B/xx unknown
- 2007-06-29 ES ES07786932T patent/ES2752460T3/es active Active
- 2007-06-29 AU AU2007271828A patent/AU2007271828B2/en not_active Ceased
- 2007-06-29 CA CA002656217A patent/CA2656217A1/en not_active Abandoned
- 2007-06-29 CN CNA2007800262750A patent/CN101489533A/zh active Pending
- 2007-06-29 CA CA002656233A patent/CA2656233A1/en not_active Abandoned
- 2007-06-29 CN CN2012101088434A patent/CN102631874A/zh active Pending
- 2007-06-29 CN CNA2007800263575A patent/CN101489534A/zh active Pending
- 2007-06-29 ZA ZA200900031A patent/ZA200900031B/xx unknown
- 2007-06-29 CA CA2656229A patent/CA2656229C/en active Active
- 2007-06-29 WO PCT/EP2007/056563 patent/WO2008006715A2/en not_active Ceased
- 2007-06-29 AU AU2007271831A patent/AU2007271831B2/en not_active Ceased
- 2007-06-29 JP JP2009518834A patent/JP2009542763A/ja active Pending
- 2007-06-29 US US12/309,306 patent/US20090175953A1/en not_active Abandoned
- 2007-06-29 CN CNA2007800262267A patent/CN101489531A/zh active Pending
- 2007-06-29 ZA ZA200900028A patent/ZA200900028B/xx unknown
- 2007-06-29 AU AU2007271830A patent/AU2007271830B2/en not_active Ceased
- 2007-06-29 AP AP2008004713A patent/AP2008004713A0/xx unknown
- 2007-06-29 US US12/309,294 patent/US8821932B2/en active Active
- 2007-06-29 EP EP11005053A patent/EP2387992A1/en not_active Ceased
- 2007-06-29 BR BRPI0714177-7A patent/BRPI0714177A2/pt not_active IP Right Cessation
- 2007-06-29 BR BRPI0714230-7A patent/BRPI0714230A2/pt not_active IP Right Cessation
- 2007-06-29 MX MX2009000307A patent/MX2009000307A/es not_active Application Discontinuation
- 2007-06-29 EP EP07786932.9A patent/EP2040680B1/en active Active
- 2007-06-29 EP EP07765734A patent/EP2040678A2/en not_active Withdrawn
- 2007-06-29 EP EP11005052A patent/EP2386292A1/en active Pending
- 2007-06-29 CN CN2012101088167A patent/CN102671585A/zh active Pending
- 2007-06-29 WO PCT/EP2007/056560 patent/WO2008006712A2/en not_active Ceased
- 2007-06-29 JP JP2009518833A patent/JP2009542762A/ja active Pending
- 2007-06-29 ZA ZA200900027A patent/ZA200900027B/xx unknown
- 2007-06-29 ZA ZA200900029A patent/ZA200900029B/xx unknown
- 2007-06-29 BR BRPI0722376-5A patent/BRPI0722376A2/pt not_active IP Right Cessation
- 2007-06-29 WO PCT/EP2007/056561 patent/WO2008006713A2/en not_active Ceased
- 2007-07-11 TW TW096125298A patent/TW200812694A/zh unknown
- 2007-07-12 CL CL2007002031A patent/CL2007002031A1/es unknown
- 2007-07-12 CL CL2007002030A patent/CL2007002030A1/es unknown
- 2007-07-12 CL CL2007002032A patent/CL2007002032A1/es unknown
- 2007-07-13 JP JP2009518979A patent/JP2009542794A/ja active Pending
- 2007-07-13 CN CNA2007800338285A patent/CN101516340A/zh active Pending
- 2007-07-13 CA CA002657548A patent/CA2657548A1/en not_active Abandoned
- 2007-07-13 AU AU2007274039A patent/AU2007274039A1/en not_active Abandoned
- 2007-07-13 AR ARP070103118A patent/AR061992A1/es not_active Application Discontinuation
- 2007-07-13 AU AU2007274041A patent/AU2007274041A1/en not_active Abandoned
- 2007-07-13 ZA ZA200900345A patent/ZA200900345B/xx unknown
- 2007-07-13 BR BRPI0714352-4A patent/BRPI0714352A2/pt not_active IP Right Cessation
- 2007-07-13 CN CNA2007800338444A patent/CN101516341A/zh active Pending
- 2007-07-13 AR ARP070103117A patent/AR061991A1/es not_active Application Discontinuation
- 2007-07-13 BR BRPI0714351-6A patent/BRPI0714351A2/pt not_active IP Right Cessation
- 2007-07-13 US US12/309,343 patent/US20100008995A1/en not_active Abandoned
- 2007-07-13 US US12/309,344 patent/US8945626B2/en not_active Expired - Fee Related
- 2007-07-13 JP JP2009518980A patent/JP2009542795A/ja active Pending
- 2007-07-13 ZA ZA200900347A patent/ZA200900347B/xx unknown
- 2007-07-13 WO PCT/GB2007/050408 patent/WO2008007151A2/en not_active Ceased
- 2007-07-13 JP JP2009518978A patent/JP2009542793A/ja active Pending
- 2007-07-13 WO PCT/GB2007/050409 patent/WO2008007152A2/en not_active Ceased
- 2007-07-13 AR ARP070103116A patent/AR061990A1/es not_active Application Discontinuation
- 2007-07-13 WO PCT/GB2007/050407 patent/WO2008007150A1/en not_active Ceased
- 2007-07-13 CA CA002657582A patent/CA2657582A1/en not_active Abandoned
- 2007-07-13 AU AU2007274040A patent/AU2007274040A1/en not_active Abandoned
- 2007-07-13 CA CA002657586A patent/CA2657586A1/en not_active Abandoned
- 2007-07-13 CN CNA2007800338942A patent/CN101516342A/zh active Pending
- 2007-07-13 US US12/309,341 patent/US7691873B2/en not_active Expired - Fee Related
- 2007-07-13 BR BRPI0714353-2A patent/BRPI0714353A2/pt not_active Application Discontinuation
-
2008
- 2008-12-11 IL IL195911A patent/IL195911A0/en unknown
- 2008-12-15 IL IL195933A patent/IL195933A/en not_active IP Right Cessation
-
2010
- 2010-05-11 AU AU2010201900A patent/AU2010201900A1/en not_active Abandoned
- 2010-05-19 CL CL2010000516A patent/CL2010000516A1/es unknown
- 2010-06-08 JP JP2010131047A patent/JP2010202665A/ja not_active Withdrawn
- 2010-06-23 AR ARP100102205A patent/AR077195A2/es not_active Application Discontinuation
-
2012
- 2012-02-03 US US13/365,830 patent/US20120135058A1/en not_active Abandoned
- 2012-02-03 US US13/365,826 patent/US20120134940A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110074993A (zh) * | 2019-06-05 | 2019-08-02 | 山东大学 | 一种制备紫外吸收剂纳米颗粒的方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102631874A (zh) | 纳米分散体的相关改进 | |
| EP2624819A1 (en) | Processes for preparing improved compositions | |
| EP1841811B1 (en) | Improvements relating to rapidly dissolving compositions | |
| CN101941675A (zh) | 纳米颗粒及其制备方法 | |
| CA2735698A1 (en) | Improvements relating to pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120815 |